<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Combretastatin Angiogenesis Vascular endothelial growth factor A Cancer research Enhanced permeability and retention effect Proteases in angiogenesis Medicine Angiology Vascular-targeting agent |
| Opportunities in Biotechnology August 2009 Deborah Rathjen - CEO & Managing Director Safe Harbor Statement Factors Affecting Future PerformanceDocID: 14B9q - View Document |
| To Our Stockholders: As OXiGENE’s newly appointed President and Chief Executive Officer, it is a pleasure to have the opportunity to provide you with an update on OXiGENE’s progress this year and our outlook for theDocID: ep8M - View Document |
| NPI[removed]ADVANCE P2 PR 18Mar09FINALDocID: eo9W - View Document |
| Microsoft Word - NPI[removed]ADVANCE PR FINAL.docxDocID: emB8 - View Document |
| 1 Tumor Vasculature: a Target for Anticancer Therapies Dietmar W. Siemann 1.1DocID: cdlw - View Document |